Skip Navigation

CAR T-Cell Therapy for Lymphoma

  • CAR T-cell therapy is a promising treatment for some patients with aggressive non-Hodgkin lymphoma (NHL) that has not responded to other therapies (refractory). It is a highly-specialized therapy that involves genetically modifying a patient's own T cells to attack their cancer. The FDA has approved several CAR T-cell therapies for lymphoma. Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) is one of the first centers to make the FDA-approved therapies available as standard of care to patients who have not had effective treatment options.

    • Yescarta (also referred to as axicabtagene ciloleucel) is approved for aggressive, relapsed and/or refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, and transformed follicular lymphoma. The clinical trials of Yescarta showed the therapy to be highly effective with 82 percent of patients responding to the CAR T-cell therapy, including 54 percent who had a complete response (i.e., no sign of cancer). The most recent follow-up data shows that at a median 15.4 months after treatment, 40 percent of patients remain in complete remission, showing the lasting effectiveness of this therapy.
    • Kymriah (also referred to as tisagenlecleucel) is approved for patients with relapsed or refractory (r/r) large B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. In clinical trials, patients had strong responses from this therapy: 53 percent responded to treatment, with 40 percent achieving a complete response (i.e. no sign of cancer). Kymriah is also approved for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) up to age 25. Learn more about Kymriah for pediatric B-cell ALL.
    • Tecartus (also referred to as brexucabtagene autoleucel, formerly KTE-X19) is approved for patients with relapsed or refractory mantle cell lymphoma. In clinical trials of Tecartus, 87 percent of patients responded to the therapy, and 62 percent had a complete response.

    Our program also offers patients clinical trials of CAR T-cell therapy for other forms of lymphoma as well as trials of CAR T-cell therapy earlier in treatment and in combination with other immunotherapies.

    Patients are evaluated carefully to determine if this therapy is appropriate for them. Learn more about CAR T-cell therapy.

    DF/BWCC also offers clinical trials evaluating CAR T-cell therapy for other forms of lymphoma.

  • Caron Jacobson, MD, detailed the research that led to FDA approval of CAR T-cell therapy for mantle cell lymphoma in July 2020.

  • Dana-Farber/ Brigham and Women's Cancer Center
  • Contact Information for CAR T-Cell Therapy

    For more information about CAR T-cell therapy, please call 877-801-CART (2278).

  • Pediatric CAR T-Cell Therapy

    Dana-Farber/Boston Children's is a certified treatment center for providing the recently FDA-approved CAR T-cell therapy called KYMRIAH to patients who are up to 25 years old with second or later relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).

  • Caron Jacobson, MD, Medical Director of the Immune Effector Cell Therapy program, discussed the first approval of chimeric antigen receptor (CAR) T-cell therapy for certain patients with non-Hodgkin lymphoma in October 2017.